Texas Researchers Summarize Promising Research on New Mesothelioma...
The authors of a new report on bevacizumab (Avastin) say there continues to be good evidence that the VEGF-inhibitor can boost the effectiveness of mesothelioma chemotherapy.(PRWeb May 02, 2017)Read the full story at http://www.prweb.com/releases/2017/05/prweb14296837.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news